European Fosamax Study: Bisphosphonate Use Connected to Atypical Femur Fractures
A report published in the May 5, 2011 issue of the New England Journal of Medicine provides further confirmation that there is, in fact, a causal link between the widely criticized osteoporotic drug, Fosamax, and atypical femur fractures. In conducting this latest Fosamax study, Swedish researchers analyzed data on 12,777 women, aged 55 and older, who suffered femur fracture injuries in 2008. The researchers concluded that there is a 47.3 percent relative risk of sustaining atypical femur fractures in patients using bisphosphonates, such as Fosamax. Perhaps what is most startling to those who have questioned and debated whether bisphosphonates such as Fosamax are safe, is that these drugs are intended to help post-menopausal women who suffer from osteoporosis by building bone strength and preventing fractures. Instead, Fosamax and other bisphosphonates are causing injuries, such as atypical femur fractures, that they are prescribed to prevent.
- Fosamax And Femur Fractures: A Close Look At An Important New Study
- Fosamax Side Effects
- Fosamax Jaw Deterioration
- Fosamax Femur Fracture
- Fosamax Heart Condition
- Fosamax Warnings
- Fosamax Lawsuit
- Fosamax Lawyer
- Fosamax Jaw
- Fosamax Warning
- Fosamax Lawsuits
- Fosamax Attorney
- Fosamax Femur Fractures
- Fosamax Injuries
- Fosamax Side Effects: Femur Fractures and Jaw Disease
Dangerous Drug Alert
Detailed Findings of the Fosamax Study
Dr. Per Aspenberg, a professor of orthopedics at Linkoping University, was the lead researcher of the Fosamax study. Of the 12,777 women observed, 59 of them sustained atypical femur fractures. 78 percent of those who sustained atypical femur fractures took bisphosphonates, compared with 10 percent of a control group. Most importantly, this Fosamax study served to reinforce earlier findings. First, long-term use increases the risk of atypical femur fractures – for every 100 days of bisphosphonate use, the risk of sustaining atypical femur fractures increases by 30 percent. Second, the risk of atypical femur fractures declines by 70 percent per year once bisphosphonate use is stopped.
In light of this latest Fosamax study, Dr. Elizabeth Shane, a professor of medicine at Columbia University who chairs a task force created by the American Society of Bone and Mineral Research to study this issue, is working to establish a national registry of patients who have sustained atypical femur fractures.
Fosamax Atypical Femur Fracture Lawsuit
If you or a loved one sustained an atypical femur fracture as a result of Fosamax use, you may be able to file a lawsuit seeking compensation for your medical expenses, pain and suffering, lost wages and more. Contact one of our Fosamax lawyers today for a free and confidential evaluation. The lawyers at Bernstein Liebhard LLP have extensive litigation experience, and have recovered billions of dollars for their clients. In addition to being staunch advocates for your claim, our Fosamax injury lawyers also provide personal attention to guide you through the complex litigation process.